Delårsrapport 1 2020 januari - mars 2020
April 28, 2020 02:30 ET
|
Northbaze Group AB
Q1 2020 1 januari – 31 mars 2020 i korthet Northbaze Group ökar sin nettoomsättning med 27 % under årets första kvartal i jämförelse med föregående års första kvartal. Omsättningen inom affärsområdet...
How to Select Office Paper that Impacts Productivity, Profitability in 2020
January 14, 2020 09:00 ET
|
Boise Paper Holdings LLC
CHICAGO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Office paper may seem like a small expense to many people, but business owners know it can directly impact their productivity and profitability. As small...
Les résultats financiers d'Emerald Health Therapeutics au deuxième trimestre 2019 indiquent un doublement des ventes pour le deuxième trimestre consécutif
August 30, 2019 05:10 ET
|
Emerald Health Therapeutics Inc.
VANCOUVER, Colombie-Britannique, 30 août 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV : EMH ; OTCQX : EMHTF) a communiqué aujourd'hui ses résultats financiers...
Emerald Health Therapeutics Reports Second Quarter 2019 Financial Results; Sales Double Second Quarter in a Row
August 29, 2019 07:00 ET
|
Emerald Health Therapeutics Inc.
VANCOUVER, British Columbia, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the quarter ended June 30,...
La coentreprise Pure Sunfarms d'Emerald Health Therapeutics a réalisé un chiffre d'affaires de 32 millions $ au deuxième trimestre, une marge d'EBITDA de 78 %, un coût de production global de 0,65 $/g et un troisième trimestre de rentabilité consécutif
August 13, 2019 11:32 ET
|
Emerald Health Therapeutics Inc.
VICTORIA, Colombie-Britannique, 13 août 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV: EMH, OTCQX: EMHTF) a publié des résultats financiers préliminaires non...
Emerald Health Therapeutics’ Pure Sunfarms JV Reaches Q2 Sales of $32 Million, 78% EBITDA Margin, $0.65/Gram All-in Production Cost, and Third Consecutive Quarter of Profitability
August 13, 2019 00:19 ET
|
Emerald Health Therapeutics Inc.
VICTORIA, British Columbia, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the...
Emerald Health Therapeutics Appoints Chief Executive Officer
July 30, 2019 07:00 ET
|
Emerald Health Therapeutics Inc.
Riaz Bandali has driven innovation, sales, and profitability in a number of global life science companies Emerald also adds Chief Commercial Officer VICTORIA, British Columbia, July 30, 2019 ...
CapStar Reports Fully Diluted EPS of $0.25 and Fully Diluted Operating EPS of $0.28 for 1Q2019
April 24, 2019 16:20 ET
|
CapStar Financial Holdings, Inc.
NASHVILLE, Tenn., April 24, 2019 (GLOBE NEWSWIRE) -- CapStar Financial Holdings, Inc. (“CapStar”) (NASDAQ:CSTR) reported net income of $4.78 million, or $0.25 per share on a fully diluted basis, for...
Traditional cost-cutting measures aren’t enough to solve current profitability crisis in Financial Services industry
February 05, 2019 09:58 ET
|
PwC
NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- In a new report titled: The productivity agenda – moving beyond cost reduction in financial services, PwC sets out the important challenges and...
CapStar Reports Fully Diluted EPS of ($0.04) and Fully Diluted Operating EPS of $0.33 for 4Q 2018
January 24, 2019 19:09 ET
|
CapStar Financial Holdings, Inc.
NASHVILLE, Tenn., Jan. 24, 2019 (GLOBE NEWSWIRE) -- CapStar Financial Holdings, Inc. (“CapStar”) (NASDAQ:CSTR) reported a net loss of ($0.7) million, or ($0.04) per share on a fully diluted basis,...